Vera Therapeutics (NASDAQ:VERA) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Vera Therapeutics (NASDAQ:VERA) issued its quarterly earnings results on Thursday. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.05), Zacks reports. During the same period last year, the business posted ($0.72) EPS.

Vera Therapeutics Price Performance

VERA stock traded up $0.67 on Thursday, reaching $42.35. The company had a trading volume of 1,953,561 shares, compared to its average volume of 884,260. The company’s fifty day moving average is $46.53 and its 200 day moving average is $35.35. The company has a market cap of $2.97 billion, a P/E ratio of -10.61 and a beta of 1.16. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21. Vera Therapeutics has a 1 year low of $18.53 and a 1 year high of $56.05.

Vera Therapeutics News Summary

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: FDA priority review and NEJM/ASN recognition for atacicept — Vera reported positive Phase 3 ORIGIN‑3 data for atacicept in IgA nephropathy that were presented at ASN Kidney Week and published in the New England Journal of Medicine. The FDA has granted priority review for the atacicept BLA with a PDUFA date of July 7, 2026, and the company expects a potential U.S. commercial launch in mid‑2026. Management also said recent 2025 equity and debt financings leave the company well‑capitalized into and beyond approval and launch. Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
• Neutral Sentiment: Financials/earnings update — Vera released FY‑2025 results and quarterly EPS figures; one report shows EPS of ($1.39) for the quarter (slightly missing consensus by ~$0.05). The results highlight continued operating losses but the company emphasizes runway provided by recent financings. Investors will focus on how close the company is to commercialization economics once/if atacicept is approved. View Press Release
• Negative Sentiment: Concentrated insider selling — multiple senior executives (including the CEO, CFO, COO and other officers) sold shares on Feb 23 at roughly $42/share (CEO Marshall Fordyce sold ~16,925 shares; other officers also reduced holdings). Such clustered insider sales can prompt investor caution and short‑term selling pressure despite the regulatory progress. Vera Therapeutics Insider Sells

Insider Buying and Selling

In related news, CEO Marshall Fordyce sold 16,925 shares of the business’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $710,511.50. Following the completion of the transaction, the chief executive officer owned 257,163 shares of the company’s stock, valued at approximately $10,795,702.74. The trade was a 6.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Joseph R. Young sold 3,117 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total transaction of $130,851.66. Following the transaction, the senior vice president directly owned 64,722 shares in the company, valued at $2,717,029.56. The trade was a 4.59% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 33,490 shares of company stock valued at $1,405,910. Company insiders own 16.30% of the company’s stock.

Institutional Trading of Vera Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Los Angeles Capital Management LLC purchased a new position in shares of Vera Therapeutics during the 4th quarter worth about $46,000. Quantbot Technologies LP purchased a new position in shares of Vera Therapeutics in the 2nd quarter valued at $51,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Vera Therapeutics during the fourth quarter worth about $71,000. Tower Research Capital LLC TRC boosted its holdings in Vera Therapeutics by 192.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after acquiring an additional 2,757 shares during the period. Finally, Sandia Investment Management LP acquired a new stake in Vera Therapeutics during the 4th quarter valued at $127,000. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on VERA shares. Pivotal Research set a $73.00 target price on Vera Therapeutics in a research note on Friday, December 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vera Therapeutics in a report on Wednesday, November 26th. TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a research note on Friday, December 5th. Evercore increased their price target on shares of Vera Therapeutics from $75.00 to $97.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Vera Therapeutics in a research note on Friday, November 28th. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.18.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.